846 related articles for article (PubMed ID: 37669923)
1. Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X; Yu T; Li X; Zhang N; Foster LJ; Peng C; Huang W; He G
Signal Transduct Target Ther; 2023 Sep; 8(1):335. PubMed ID: 37669923
[TBL] [Abstract][Full Text] [Related]
2. Strategies for targeting undruggable targets.
Zhang G; Zhang J; Gao Y; Li Y; Li Y
Expert Opin Drug Discov; 2022 Jan; 17(1):55-69. PubMed ID: 34455870
[TBL] [Abstract][Full Text] [Related]
3. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.
Lu Y; Yang Y; Zhu G; Zeng H; Fan Y; Guo F; Xu D; Wang B; Chen D; Ge G
Int J Biol Sci; 2023; 19(11):3360-3382. PubMed ID: 37496997
[TBL] [Abstract][Full Text] [Related]
4. Big data and artificial intelligence discover novel drugs targeting proteins without 3D structure and overcome the undruggable targets.
He H; Liu B; Luo H; Zhang T; Jiang J
Stroke Vasc Neurol; 2020 Dec; 5(4):381-387. PubMed ID: 33376199
[TBL] [Abstract][Full Text] [Related]
5. Reimagining Druggability Using Chemoproteomic Platforms.
Spradlin JN; Zhang E; Nomura DK
Acc Chem Res; 2021 Apr; 54(7):1801-1813. PubMed ID: 33733731
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Covalent Inhibition in Drug Discovery: Filling the Void in Literature.
Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
Curr Top Med Chem; 2018; 18(13):1135-1145. PubMed ID: 30068277
[TBL] [Abstract][Full Text] [Related]
8. [Advances in applications of activity-based chemical probes in the characterization of amino acid reactivities].
Li J; Wang G; Ye M; Qin H
Se Pu; 2023 Jan; 41(1):14-23. PubMed ID: 36633073
[TBL] [Abstract][Full Text] [Related]
9. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
Yu Q; Xiong X; Sun Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
[TBL] [Abstract][Full Text] [Related]
10. Taking Aim at the Undruggable.
Coleman N; Rodon J
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-8. PubMed ID: 33989024
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Developing Small Molecules Targeting Nucleic Acid.
Wang M; Yu Y; Liang C; Lu A; Zhang G
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27248995
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles of allosteric modulators in the regulation of protein-protein interactions (PPIs): A new paradigm for PPI drug discovery.
Ni D; Lu S; Zhang J
Med Res Rev; 2019 Nov; 39(6):2314-2342. PubMed ID: 30957264
[TBL] [Abstract][Full Text] [Related]
13. Current strategies and progress for targeting the "undruggable" transcription factors.
Zhuang JJ; Liu Q; Wu DL; Tie L
Acta Pharmacol Sin; 2022 Oct; 43(10):2474-2481. PubMed ID: 35132191
[TBL] [Abstract][Full Text] [Related]
14. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
15. Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.
Kim J
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069255
[TBL] [Abstract][Full Text] [Related]
16. Fragment-based drug discovery supports drugging 'undruggable' protein-protein interactions.
Wang ZZ; Shi XX; Huang GY; Hao GF; Yang GF
Trends Biochem Sci; 2023 Jun; 48(6):539-552. PubMed ID: 36841635
[TBL] [Abstract][Full Text] [Related]
17. Targeted Protein Degradation: An Important Tool for Drug Discovery for "Undruggable" Tumor Transcription Factors.
Dai M; Radhakrishnan S; Li R; Tan R; Yan K; Fan G; Liu M
Technol Cancer Res Treat; 2022; 21():15330338221095950. PubMed ID: 35466792
[TBL] [Abstract][Full Text] [Related]
18. Targeted protein degradation in drug development: Recent advances and future challenges.
Song J; Hu M; Zhou J; Xie S; Li T; Li Y
Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
[TBL] [Abstract][Full Text] [Related]
19. Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.
Yin G; Huang J; Petela J; Jiang H; Zhang Y; Gong S; Wu J; Liu B; Shi J; Gao Y
Signal Transduct Target Ther; 2023 May; 8(1):212. PubMed ID: 37221195
[TBL] [Abstract][Full Text] [Related]
20. Development and application of novel electrophilic warheads in target identification and drug discovery.
Liu Y; Lv S; Peng L; Xie C; Gao L; Sun H; Lin L; Ding K; Li Z
Biochem Pharmacol; 2021 Aug; 190():114636. PubMed ID: 34062128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
